Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Science. Author manuscript; available in PMC 2006 October 7.
Published in final edited form as:
PMCID: PMC1482474

Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome


Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor–β (TGF-β) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists such as TGF-β–neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.

MFS is a systemic disorder of connective tissue caused by mutations in FBN1, the gene encoding fibrillin-1 (1). As a principal component of the extracellular matrix microfibril (2, 3), fibrillin-1 was initially thought to play primarily a structural role in connective tissue. Several lines of evidence support an additional role as a regulator of the cytokine TGF-β (4, 5). Mice homozygous for a hypomorphic Fbn1 allele have impaired pulmonary alveolar septation associated with increased TGF-β signaling that can be prevented by perinatal administration of a polyclonal TGF-β neutralizing antibody (NAb) (5). Similarly, myxomatous thickening of the cardiac atrioventricular valves in mice harboring a Fbn1 missense mutation is attenuated by perinatal systemic administration of TGF-β NAb (6).

We sought to determine the role of TGF-β in MFS-associated aortic aneurysm, which is the major life-threatening manifestation of this condition. We studied mice heterozygous for an Fbn1 allele encoding a cysteine substitution, Cys1039 → Gly (C1039G), in an epidermal growth factor–like domain of fibrillin-1 (Fbn1C1039G/+) (6-8), which is the most common class of mutation causing MFS. The aortic root in Fbn1C1039G/+ mice undergoes progressive dilatation, evident as early as 2 weeks of age. By 7 weeks of age, the aortic root in the mutant mice is larger than that in wild-type mice (1.82 ± 0.14 mm versus 1.59 ± 0.11 mm, respectively; P < 0.05). This size difference becomes more pronounced with age (aortic root at 8 months, 2.47 ± 0.33 mm versus 1.82 ± 0.11 mm; P < 0.0001).

Histologic analysis of 14-week-old Fbn1C1039G/+ mice revealed aberrant thickening of the aortic media with fragmentation and disarray of elastic fibers (fig. S1). In addition, Fbn1C1039G/+ mice showed increased collagen deposition, which is an indirect marker of increased TGF-β signaling (fig. S1) (9, 10). Phosphorylation and subsequent nuclear translocation of Smad2 (pSmad2), which are induced by TGF-β signaling (11), are markedly increased in the aortic media of Fbn1C1039G/+ mice relative to wild-type mice (fig. S1). Similar changes have been observed in aortic samples derived from patients with MFS (12).

To investigate whether excessive TGF-β signaling plays a causal role in progressive aortic root enlargement, we treated mice postnatally with TGF-β NAb after the establishment of aortic root aneurysm (Fig. 1). Treatment by intraperitoneal injection was begun at 7 weeks of age and continued for 8 weeks. The Fbn1C1039G/+ mice received low-dose TGF-β NAb (1 mg/kg body weight; Fig. 1, C and G), high-dose TGF-β NAb (10 mg/kg; Fig. 1, D and H), or placebo (10 mg/kg rabbit IgG; Fig. 1, B and F) every 2 weeks. Histologic analyses revealed reduced elastic fiber fragmentation and reduced TGF-β signaling in the aortic media of TGF-β Nab–treated mice relative to the placebo group (Fig. 1, A to H). In humans with MFS, the diameter and rate of enlargement of the aortic root are directly proportional to the risk of life-threatening aortic dissection (13). Echocardiograms revealed that the aortic root diameter at baseline in the wild-type mice (1.57 ± 0.05 mm) was smaller than that in the three Fbn1C1039G/+ treatment arms [placebo, 1.75 ± 0.15 mm; NAb (10 mg/kg), 1.80 ± 0.11 mm; NAb (1 mg/kg), 1.86 ± 0.15 mm; P < 0.0001 for each treatment arm relative to wild type]. There was no difference in the growth rate of the aortic root, as assessed by echocardiograms performed after 8 weeks of treatment, between wild-type mice and either of the TGF-β NAb treatment groups (P = 0.11). In contrast, the aortic root growth rate in the placebo-treated mice was greater than that in either wild-type (P < 0.0001) or NAb-treated mice (P < 0.03, Fig. 1I). After 8 weeks, aortic wall thickness in NAb-treated Fbn1C1039G/+ mice was indistinguishable from that in untreated wild-type mice (P = 0.91) and less than that in the placebo group (P < 0.01, Fig. 1J). Aortic wall architecture was disrupted in Fbn1C1039G/+ mice relative to wild-type mice (P < 0.0001) but improved in mutant mice treated with NAb (P < 0.001, Fig. 1K). These data show that excessive TGF-β signaling contributes to the formation of aortic aneurysm in a mouse model of MFS, and that TGF-β antagonism represents a productive treatment strategy.

Fig. 1
Postnatal treatment with TGF-β NAb. (A to H) Characterization of the ascending aorta in untreated wild-type mice [(A) and (E)] and Fbn1C1039G/+ mice treated with placebo [(B) and (F)], 1 mg/kg TGF-β NAb [(C) and (G)], and 10 mg/kg TGF-β ...

We became interested in losartan, an angiotensin II type 1 receptor (AT1) antagonist, not only because it lowers blood pressure—a desirable effect in patients with aortic aneurysm—but also because it leads to antagonism of TGF-β in animal models of chronic renal insufficiency and cardiomyopathy (14, 15). Using a prenatal administration protocol in our mouse model, we compared the efficacy of losartan to that of propranolol, which is representative of β-adrenergic blocking agents widely used in patients with MFS to slow the rate of aortic growth (16). The doses of losartan and propranolol were titrated to achieve comparable hemodynamic effects in vivo, including a 15 to 20% decrease in heart rate and a 10 to 20% decrease in blood pressure in both groups.

Pregnant Fbn1C1039G/+ mice received losartan (0.6 g/liter), propranolol (0.5 g/liter), or placebo in their drinking water, beginning at 2 weeks of gestation. Treatment of the mothers continued throughout lactation and was maintained in the pups after weaning. Mice were killed at 10 months of age. Elastic fiber fragmentation was observed in both placebo- and propranolol-treated mice, but not in losartan-treated mice (Fig. 2, A to D). The average aortic wall thickness for untreated wild-type animals was smaller than that in placebo-treated Fbn1C1039G/+ mice (P < 0.0001) but was indistinguishable from that in losartan-treated Fbn1C1039G/+ mice (P = 0.24, Fig. 2E). Aortic wall thickness in the propranolol-treated mice was indistinguishable from that in the placebo group (P = 0.19). Likewise, aortic wall architecture was normalized in losartan-treated Fbn1C1039G/+ animals relative to the placebo group (P < 0.0001) but was not influenced by propranolol (P = 0.16, Fig. 2F). There was marked aortic dilatation in the placebo- and propranolol-treated mutant mice, whereas the losartan-treated mutant mice were indistinguishable from wild-type littermates (fig. S2).

Fig. 2
Prenatal treatment with losartan and propranolol. (A to D) VVG staining highlights intact elastic fiber architecture and normal ascending aortic wall thickness (arrows) in wild-type mice (A) and losartan-treated Fbn1C1039G/+ mice (D). Marked elastic fiber ...

Because MFS is typically diagnosed after birth and because the use of AT1 antagonists is contraindicated during pregnancy (17), we investigated whether losartan could attenuate or prevent abnormal aortic root growth if treatment were initiated postnatally, after the establishment of aortic aneurysms. At 7 weeks of age, after echocardiographic documentation of aneurysm (fig. S3), Fbn1C1039G/+ mice received placebo, propranolol (0.5 g/liter), or losartan (0.6 g/liter) in their drinking water. Baseline echocardiograms revealed no differences in aortic root size between any of the treatment groups for Fbn1C1039G/+ mice (placebo 1.83 ± 0.11 mm, propranolol 1.92 ± 0.27 mm, losartan 1.84 ± 0.08 mm, respectively; P = 0.5). However, before treatment, the aortic diameter in Fbn1C1039G/+ mice was always greater than in untreated wild-type mice (1.59 ± 0.11 mm; P < 0.002) (fig. S3).

Three independent aortic root measurements were obtained for each mouse every 2 months during the 6 months of treatment. Mice were killed at 8 months of age. In contrast to propranolol or placebo, losartan treatment prevented elastic fiber fragmentation (Fig. 3, A to D) and blunted TGF-β signaling in the aortic media, as evidenced by reduced nuclear accumulation of pSmad2 (Fig. 3, E to H). The aortic root growth rate over this period was less in the wild-type mice than in the placebo-treated Fbn1C1039G/+ mice (P < 0.0001, Fig. 3I). Although the propranolol-treated Fbn1C1039G/+ mice did show a slower rate of aortic root growth than did placebo-treated animals (P < 0.001), this growth rate remained greater than that in untreated wild-type mice (P < 0.04). In contrast, the aortic root growth rate in losartan-treated Fbn1C1039G/+ mice was indistinguishable from that in the wild-type group (P = 0.55, Fig. 3I). Furthermore, the absolute diameter of the aortic root at the end of treatment was similar in the losartan-treated Fbn1C1039G/+ mice and untreated wild-type littermates (P = 0.32; fig. S3). Propranolol had no discernable effect on either aortic wall thickness or elastic fiber architecture when compared to placebo; hence, its beneficial effect is limited to slowing the rate of growth of the aortic root. In contrast, losartan-treated Fbn1C1039G/+ mice showed improvement in all three parameters compared to placebo-treated mice, with full normalization relative to wild-type mice (Fig. 3, I to K). We conclude that β-adrenergic blockade with propranolol diminishes aortic growth rate in this model of MFS but does not prevent progressive deterioration of aortic wall architecture or ongoing abnormal aortic dilatation. In contrast, AT1 blockade with losartan appears to achieve full correction of the phenotypic abnormalities in the aortic wall of Fbn1C1039G/+ mice.

Fig. 3
Postnatal treatment with losartan and propranolol. (A to H) VVG staining [(A) to (D)] and pSmad2 immunostaining [(E) to (H)] of aortic wall. Elastic lamellae are intact and aortic media is of normal thickness in the wild-type (A) and losartan-treated ...

In a previous study, we showed that a different strain of mice homozygous for hypomorphic Fbn1 alleles showed widening of the distal airspace due to failure of alveolar septation (5). This abnormality correlated with increased TGF-β signaling and was prevented by prenatal administration of TGF-β NAb (5). To determine whether losartan can improve this lung phenotype when administered postnatally—a matter of specific relevance to patients with MFS—we treated Fbn1C1039G/+ mice with losartan beginning at 7 weeks of age. After 6 months of treatment, placebo-treated Fbn1C1039G/+ mice showed widening of the distal airspace due to impaired alveolar septation (mean linear intercept 84.3 ± 15 mm) relative to wild-type placebo-treated mice (mean linear intercept 41.3 ± 5 μm, P < 0.001; Fig. 4). Losartan-treated Fbn1C1039G/+ mice showed a reduction in distal airspace caliber relative to placebo-treated Fbn1C1039G/+ animals (mean linear intercept 53.9 ± 12 μm, P < 0.001; Fig. 4).

Fig. 4
Postnatal losartan treatment of lung disease in Fbn1C1039G/+ mice. Histologic analysis of lung in wild-type mice (A) shows normal airspace caliber. Fbn1C1039G/+ mice treated with placebo (B) show diffuse distal airspace widening (example delineated with ...

AT1 antagonism might achieve superior protection over β-adrenergic blocking agents by virtue of increased blunting of the hemodynamic stress that is imposed on a structurally deficient aortic wall, as opposed to a mechanism relevant to TGF-β signaling or other molecular pathogenetic events. Four lines of evidence argue against this hypothesis. First, the doses of losartan and propranolol were titrated to achieve comparable hemodynamic effects. Second, isolated antagonism of TGF-β signaling with NAb provides similar protection. Third, analysis of pSmad2 nuclear staining revealed that losartan antagonizes TGF-β signaling in the aortic wall of Fbn1C1039G/+ mice, an event seen in NAb-treated mice but not in propranolol-treated mice (Fig. 3, G and H). Fourth, we demonstrate here that losartan can improve disease manifestations in the lungs (Fig. 4), an event that cannot plausibly relate to improved hemodynamics.

The mechanism by which AT1 blockade antagonizes TGF-β signaling remains to be fully elucidated. Signaling through the AT1 receptor increases the expression of TGF-β ligands and receptors and also induces the expression of thrombospondin-1, a potent activator of TGF-β (18-21). In the vessel wall, AT1 signaling stimulates proliferation of vascular smooth muscle cells (VSMCs) and vessel wall fibrosis (22), although this may be context-dependent. In avian systems, neural crest– and mesoderm-derived VSMCs (N- and M-VSMCs, respectively) respond differently to TGF-β1, with cellular proliferation and fibrosis seen in the former and growth inhibition seen in the latter (23, 24). This differential response may explain the particular predisposition of the root of the aorta—a vascular segment enriched for N-VSMCs—to undergo dilatation and dissection in MFS. The pulmonary artery root is also enriched for N-VSMCs and routinely shows dilatation in MFS despite the reduced pressure in the pulmonary circulation (25).

Given that signaling through the angiotensin II type 2 receptor (AT2) antagonizes many of the effects that are promoted by AT1 signaling (26), specific AT1 antagonism may be preferable to the dual AT1/AT2 blockade achieved with angiotensin converting enzyme (ACE) inhibitors. Consistent with this hypothesis, Daugherty and colleagues found that the formation of angiotensin II–induced abdominal aortic aneurysms could be prevented in apoE−/− mice by treatment with AT1 antagonists but was accelerated in both frequency and severity upon treatment with a selective AT2 blocker (27). Nagashima and colleagues observed increased apoptosis in vessel wall explants and cultured VSMCs from individuals with MFS, and they showed that AT2 but not AT1 blockade reduced this effect (28, 29). These samples were derived from aneurysms in the 7- to 9-cm range, far beyond the current threshold for aortic root surgery. In our mouse model, we have not detected enhanced apoptosis in early and intermediate stages of aortic aneurysm (fig. S4). Angiotensin II also stimulates Smad2-dependent signaling and fibrosis in VSMCs in a TGF-β–independent manner, and this effect can be prevented by selective AT1 blockade (30). Thus, although TGF-β ligand-dependent signaling appears critical to the pathogenesis of aortic aneurysm in MFS, antagonism of a parallel pSmad2-mediated signaling cascade may contribute to the protection afforded by losartan.

The demonstration of excess TGF-β signaling in the aortic wall of patients with other aortic aneurysm syndromes, including Loeys-Dietz syndrome (caused by mutations in TGFBR1 or TGFBR2) and arterial tortuosity syndrome (caused by mutations in GLUT10), suggests that losartan may be of broad relevance in the treatment of human vasculopathies (12, 31).

Losartan is currently in widespread clinical use for treatment of hypertension and prevention of strokes in both adults and children. Given its exceptional tolerance profile in all age groups, we conclude that a prospective clinical trial in patients with MFS is indicated. Furthermore, this study is illustrative of the promise that enhanced identification of disease genes in the post–genome sequencing era will have a pronounced impact on medicine. Disease gene discovery is but an obligate first step in the process of making animal models, interrogating pathogenesis, and deriving unanticipated disease mechanisms and rational treatment strategies.

Supplementary Material

Supplementary Material


Supporting Online Material Materials and Methods Figs. S1 to S4 References

References and Notes

1. Dietz HC, et al. Nature. 1991;352:337. [PubMed]
2. Sakai LY, Keene DR, Glanville RW, Bachinger HP. J. Biol. Chem. 1991;266:14763. [PubMed]
3. Visconti RP, Barth JL, Keeley FW, Little CD. Matrix Biol. 2003;22:109. [PubMed]
4. Isogai Z, et al. J. Biol. Chem. 2003;278:2750. [PubMed]
5. Neptune ER, et al. Nat. Genet. 2003;33:407. [PubMed]
6. Ng CM, et al. J. Clin. Invest. 2004;114:1586. [PMC free article] [PubMed]
7. Judge DP, et al. J. Clin. Invest. 2004;114:172. [PMC free article] [PubMed]
8. Jones KB, et al. Spine. 2005;30:291. [PubMed]
9. Rossi P, et al. Cell. 1988;52:405. [PubMed]
10. Schlumberger W, Thie M, Rauterberg J, Robenek H. Arterioscler. Thromb. 1991;11:1660. [PubMed]
11. Heldin CH, Miyazono K, ten Dijke P. Nature. 1997;390:465. [PubMed]
12. Loeys BL, et al. Nat. Genet. 2005;37:275. [PubMed]
13. Gott VL, et al. N. Engl. J. Med. 1999;340:1307. [PubMed]
14. Lavoie P, et al. J. Hypertens. 2005;23:1895. [PubMed]
15. Lim DS, et al. Circulation. 2001;103:789. [PMC free article] [PubMed]
16. Shores J, Berger KR, Murphy EA, Pyeritz RE. N. Engl. J. Med. 1994;330:1335. [PubMed]
17. Spence SG, et al. Teratology. 1995;51:367. [PubMed]
18. Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Hypertension. 1994;23:587. [PubMed]
19. Wolf G, Ziyadeh FN, Stahl RA. J. Mol. Med. 1999;77:556. [PubMed]
20. Fukuda N, et al. Am. J. Hypertens. 2000;13:191. [PubMed]
21. Naito T, et al. Am. J. Physiol. Renal Physiol. 2004;286:F278. [PubMed]
22. Nabel EG, et al. Proc. Natl. Acad. Sci. U.S.A. 1993;90:10759. [PubMed]
23. Gadson PF, Jr., et al. Exp. Cell Res. 1997;230:169. [PubMed]
24. Topouzis S, Majesky MW. Dev. Biol. 1996;178:430. [PubMed]
25. Nollen GJ, et al. Heart. 2002;87:470. [PMC free article] [PubMed]
26. Jones ES, Black MJ, Widdop RE. J. Mol. Cell. Cardiol. 2004;37:1023. [PubMed]
27. Daugherty A, Manning MW, Cassis LA. Br. J. Pharmacol. 2001;134:865. [PMC free article] [PubMed]
28. Nagashima H, et al. Circulation. 2001;104:I282. [PubMed]
29. Suzuki J, et al. Circulation. 2002;106:847. [PubMed]
30. Rodriguez-Vita J, et al. Circulation. 2005;111:2509. [PubMed]
31. Coucke PJ, et al. Nat. Genet. in press.
32. We thank K. Khan for expert technical assistance. Supported by the NIH (H.C.D., D.P.J., D.L.H., D.B.R., F.R.), the Smilow Center for Marfan Syndrome Research (H.C.D.), the National Marfan Foundation (H.C.D., D.P.J.), the Howard Hughes Medical Institute (H.C.D.), the Victor A. McKusick Endowment (H.C.D.), and the Dana and Albert “Cubby” Broccoli Center for Aortic Diseases (D.P.J.). All protocols for mouse treatment were approved by the Animal Care and Use Committee of the Johns Hopkins University School of Medicine.